File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cancers15102749
- Scopus: eid_2-s2.0-85160663559
- WOS: WOS:000997673500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
Title | Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma |
---|---|
Authors | |
Keywords | immune checkpoint inhibitor non-small cell lung cancer targeted therapy tumor immune microenvironment |
Issue Date | 13-May-2023 |
Publisher | MDPI |
Citation | Cancers, 2023, v. 15, n. 10 How to Cite? |
Abstract | The rapid development of targeted therapy paved the way toward personalized medicine for advanced non-small cell lung cancer (NSCLC). Lung adenocarcinoma (ADC) harboring actionable genetic alternations including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma virus (ALK) and c-ros oncogene 1 (ROS1) treated with tyrosine kinase inhibitors (TKIs) incurred lesser treatment toxicity but better therapeutic responses compared with systemic chemotherapy. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) have also shown an increase in overall survival (OS) for NSCLC patients. However, acquired resistance to these targeted therapies remains a major obstacle to long-term maintenance treatment for lung ADC patients. The emergence of immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD-1) or programmed cell death-ligand 1 (PD-L1) has changed the treatment paradigm for NSCLC tumors without actionable genetic alternations. Clinical studies have suggested, however, that there are no survival benefits with the combination of targeted therapy and ICIs. In this review, we will summarize and discuss the current knowledge on the tumor immune microenvironment and the dynamics of immune phenotypes, which could be crucial in extending the applicability of ICIs for this subpopulation of lung ADC patients. |
Persistent Identifier | http://hdl.handle.net/10722/331319 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.391 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwok, HH | - |
dc.contributor.author | Yang, J | - |
dc.contributor.author | Lam, DC | - |
dc.date.accessioned | 2023-09-21T06:54:40Z | - |
dc.date.available | 2023-09-21T06:54:40Z | - |
dc.date.issued | 2023-05-13 | - |
dc.identifier.citation | Cancers, 2023, v. 15, n. 10 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331319 | - |
dc.description.abstract | <p>The rapid development of targeted therapy paved the way toward personalized medicine for advanced non-small cell lung cancer (NSCLC). Lung adenocarcinoma (ADC) harboring actionable genetic alternations including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma virus (ALK) and c-ros oncogene 1 (ROS1) treated with tyrosine kinase inhibitors (TKIs) incurred lesser treatment toxicity but better therapeutic responses compared with systemic chemotherapy. Angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF) have also shown an increase in overall survival (OS) for NSCLC patients. However, acquired resistance to these targeted therapies remains a major obstacle to long-term maintenance treatment for lung ADC patients. The emergence of immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD-1) or programmed cell death-ligand 1 (PD-L1) has changed the treatment paradigm for NSCLC tumors without actionable genetic alternations. Clinical studies have suggested, however, that there are no survival benefits with the combination of targeted therapy and ICIs. In this review, we will summarize and discuss the current knowledge on the tumor immune microenvironment and the dynamics of immune phenotypes, which could be crucial in extending the applicability of ICIs for this subpopulation of lung ADC patients.</p> | - |
dc.language | eng | - |
dc.publisher | MDPI | - |
dc.relation.ispartof | Cancers | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | immune checkpoint inhibitor | - |
dc.subject | non-small cell lung cancer | - |
dc.subject | targeted therapy | - |
dc.subject | tumor immune microenvironment | - |
dc.title | Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cancers15102749 | - |
dc.identifier.scopus | eid_2-s2.0-85160663559 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 10 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.isi | WOS:000997673500001 | - |
dc.identifier.issnl | 2072-6694 | - |